All In Biotech

Drug Trial Radar · NCT03744182

A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD

Last checked: Nov 19, 2026Latest source record: Jan 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

66

Actual

Start

Nov 1, 2018

Primary completion

Mar 18, 2020

Study completion Mar 18, 2020

Sponsor

Sponsor type
Industry
First posted
Nov 16, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of HM15211 in obese subjects with NAFLD

Conditions

  • NAFLD

Interventions

  • HM15211Drug

    A sterile solution of HM15211 contained in pre-filled syringes

  • Placebo of HM15211Drug

    A sterile, matching solution in pre-filled syringes

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse EventsTime frame: 12 weeks
  2. Incidence of Clinical Renal Function Lab AbnormalitiesTime frame: baseline and 12 weeks
  3. Vital SignsTime frame: baseline and 12 weeks
  4. 12-lead ECGTime frame: baseline and 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ProSciento Inc.

    Chula Vista, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.